8-K: Alkermes Announces Positive Phase 1b Results for ALKS 2680 in Narcolepsy and Idiopathic Hypersomnia

Alkermes reports positive topline results from a Phase 1b study of ALKS 2680, showing improved wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia.

Summary

• Alkermes announced positive topline results from a Phase 1b study of ALKS 2680, an oral orexin 2 receptor agonist.
• The study evaluated ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
• The drug demonstrated statistically significant and clinically meaningful improvements in mean sleep latency compared to placebo at all doses tested.
• In the NT2 cohort (n=9), mean sleep latency improved by 12 minutes at 5mg, 19 minutes at 12mg, and 21 minutes at 25mg compared to placebo.
• In the IH cohort (n=8), mean sleep latency improved by 8 minutes at 5mg, 11 minutes at 12mg, and 18 minutes at 25mg compared to placebo.
• ALKS 2680 was generally well-tolerated across all doses in both patient groups.
• The company plans to initiate a Phase 2 study in patients with NT2 in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive results from a Phase 1b study, with clear efficacy and a good safety profile. The company is moving forward with a Phase 2 study, indicating confidence in the drug's potential. The sentiment is very positive, but tempered by the inherent risks of drug development.

Positives

• The drug demonstrated a clear dose-response relationship, indicating that higher doses led to greater improvements in wakefulness.
• The observed mean MWT scores at higher doses were within the normal range for healthy individuals, suggesting a potential for restoring normal wakefulness.
• The drug was generally well-tolerated, with most adverse events being mild and transient, indicating a favorable safety profile.
• The results support the hypothesis that orexin agonists can be effective in treating sleep disorders, even in patients without known orexin deficiency.
• The company is moving quickly to initiate a Phase 2 study, demonstrating a commitment to further development of the drug.

Negatives

• Some patients experienced mild adverse events such as pollakiuria, insomnia, and dizziness.
• One moderate case of pollakiuria was reported at the highest dose (25mg).
• A single patient reported a mild, transient occurrence of photophobia at the 25mg dose.
• A single patient reported a mild, transient occurrence of visual disturbance at the 25mg dose.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the possibility that ALKS 2680 could be ineffective or unsafe.
• Preclinical and initial clinical results may not be predictive of results in further clinical studies or real-world settings.
• There are potential risks related to changes in the cost, scope, and duration of the ALKS 2680 development program.
• Future clinical trials may not be initiated or completed on time or at all.

Future Outlook

Alkermes plans to initiate a Phase 2 study in patients with narcolepsy type 2 in the second half of 2024 and intends to submit the Phase 1b study results for publication in a peer-reviewed journal and present additional data at upcoming scientific meetings.

Management Comments

• Craig Hopkinson, M.D., Chief Medical Officer, stated that the data further validates the hypothesis that an orexin agonist has the potential to provide significant clinical benefits for both narcolepsy type 1 and type 2 patient populations.
• Ron Grunstein, M.D., Ph.D., Head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, noted that orexin agonists have the potential to transform the current treatment landscape for people living with narcolepsy.

Industry Context

This announcement is significant as it highlights the potential of orexin agonists in treating sleep disorders beyond narcolepsy type 1, which is a growing area of research and development in the pharmaceutical industry. The positive results could position Alkermes as a key player in the development of new treatments for sleep disorders.

Comparison to Industry Standards

• The improvements in mean sleep latency observed with ALKS 2680 are comparable to or better than some existing treatments for narcolepsy and idiopathic hypersomnia.
• The use of the Maintenance of Wakefulness Test (MWT) is a standard measure in sleep disorder research, allowing for direct comparison with other studies.
• The safety profile of ALKS 2680 appears favorable compared to some other drugs in this class, with most adverse events being mild and transient.
• Other companies such as Jazz Pharmaceuticals and Harmony Biosciences are also developing treatments for narcolepsy, but ALKS 2680's mechanism of action as an orexin 2 receptor agonist is a unique approach.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with narcolepsy type 2 and idiopathic hypersomnia may benefit from a new treatment option.
• Employees of Alkermes may be motivated by the positive progress of the drug development program.
• The positive results may attract potential partners or investors.

Next Steps

• Alkermes plans to initiate a Phase 2 study in patients with narcolepsy type 2 in the second half of 2024.
• The company expects to submit results from this phase 1b study to a peer-reviewed journal for publication.
• Alkermes plans to present additional ALKS 2680 study results at upcoming scientific meetings.

Key Dates

Keywords

ALKS 2680, narcolepsy, idiopathic hypersomnia, orexin 2 receptor agonist, sleep disorder, wakefulness, clinical trial, phase 1b, phase 2, sleep latency